TCCL Archive
Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival
TCCL Archive
Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis
TCCL Archive
Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL
TCCL Archive
Biomarker May Predict Prostate Cancer Metastases
TCCL Archive
Individualized Cancer Vaccines Show 90% Survival at 6 Months
TCCL Archive
Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial
TCCL Archive
Two Phase II Studies of Ibrutinib Deliver High Response Rates
TCCL Archive
NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent
TCCL Archive
Study: BRCA2-Negative Women Could Still Have High Risk
TCCL Archive
Velcade Addition Can Improve Graft-Versus-Host Outcomes
TCCL Archive
NCI CTEP Approved Trials For the Month of December
TCCL Archive
FDA Expands Nexavar Indication To Include Thyroid Cancer
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In The Headlines: Are cancer registries on the chopping block, and what does it mean if they are?
- The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills
